Luminex pays $77mm for Nanosphere
Luminex Corp. is paying $77mm ($1.70 per share; a 63% premium) in cash to acquire molecular diagnostics firm Nanosphere Inc. Luminex also agreed to retire $25mm of Nanosphere debt.
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Nanotechnology, Chips, etc.
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.